|
Index | - | P/E | - | EPS (ttm) | -1.55 | Insider Own | 20.60% | Shs Outstand | 10.23M | Perf Week | -13.57% |
Market Cap | 24.93M | Forward P/E | - | EPS next Y | -1.32 | Insider Trans | 0.00% | Shs Float | 7.87M | Perf Month | -39.50% |
Income | -13.90M | PEG | - | EPS next Q | -0.35 | Inst Own | 3.10% | Short Float | 0.45% | Perf Quarter | -33.15% |
Sales | - | P/S | - | EPS this Y | -209.80% | Inst Trans | 287.97% | Short Ratio | 2.00 | Perf Half Y | -47.96% |
Book/sh | 1.04 | P/B | 2.33 | EPS next Y | 0.80% | ROA | -97.80% | Target Price | 12.00 | Perf Year | - |
Cash/sh | 1.08 | P/C | 2.25 | EPS next 5Y | - | ROE | -105.40% | 52W Range | 2.33 - 8.74 | Perf YTD | -44.00% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -71.40% | Beta | - |
Dividend % | - | Quick Ratio | 17.90 | Sales past 5Y | - | Gross Margin | - | 52W Low | 7.30% | ATR | 0.27 |
Employees | 3 | Current Ratio | 17.90 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 30.86 | Volatility | 8.55% 8.39% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | -68.90% | Profit Margin | - | Rel Volume | 0.23 | Prev Close | 2.42 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | May 11 BMO | Payout | - | Avg Volume | 17.62K | Price | 2.50 |
Recom | 2.00 | SMA20 | -21.67% | SMA50 | -27.87% | SMA200 | -41.49% | Volume | 3,936 | Change | 3.31% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite